Key statistics
As of last trade Amneal Pharmaceuticals Inc (2DT:MUN) traded at 7.75, -1.90% below its 52-week high of 7.90, set on Sep 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.75 |
---|---|
High | 7.75 |
Low | 7.75 |
Bid | 7.85 |
Offer | 7.90 |
Previous close | 7.85 |
Average volume | 22.22 |
---|---|
Shares outstanding | 309.54m |
Free float | 129.11m |
P/E (TTM) | -- |
Market cap | 2.62bn USD |
EPS (TTM) | -0.6224 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 07:30 BST.
More ▼
Press releases
- Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
- Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
- Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
- Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
- Amneal Reports Second Quarter 2024 Financial Results
- Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
- Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
- Amneal to Report Second Quarter 2024 Results on August 9, 2024
More ▼